Cutaneous B cell pseudolymphoma treated with rituximab and methotrexate

Area of Science:

• Dermatology
• Immunology
• Oncology

Background:

• Cutaneous B cell pseudolymphoma (CBPL) is the most common pseudolymphoma, typically presenting with a benign course and good response to local therapies.
• Understanding the immunopathology of CBPL is crucial for managing refractory cases.

Observation:

• A unique case of CBPL refractory to multiple treatments is presented.
• The patient ultimately responded to a combination of rituximab and methotrexate.

Findings:

• This case illustrates the complex interaction between T and B lymphocytes in treatment-resistant CBPL.
• Perifollicular T cells may play a significant role in the resistance of CBPL to conventional treatments.
• Rituximab and methotrexate demonstrated an additive therapeutic effect, targeting both B and T cell populations.

Implications:

• The findings suggest a potential therapeutic strategy for refractory CBPL by combining B cell and T cell-targeting agents.
• This approach, combining rituximab and methotrexate, may offer a new avenue for managing challenging CBPL cases.
• Further research into the role of T cells in CBPL pathogenesis and treatment resistance is warranted.